Novartis AG (LON:0QLR)
London
· Delayed Price · Currency is GBP · Price in CHF | Market Cap | 204.74B |
| Revenue (ttm) | 42.85B |
| Net Income (ttm) | 10.25B |
| Shares Out | n/a |
| EPS (ttm) | 5.29 |
| PE Ratio | 19.98 |
| Forward PE | 16.59 |
| Dividend | 3.54 (3.00%) |
| Ex-Dividend Date | Mar 10, 2026 |
| Volume | 1,610,709 |
| Average Volume | 1,081,189 |
| Open | 113.60 |
| Previous Close | 116.20 |
| Day's Range | 113.09 - 114.28 |
| 52-Week Range | 87.99 - 131.02 |
| Beta | 0.52 |
| RSI | 31.02 |
| Earnings Date | Apr 28, 2026 |
About Novartis AG
Novartis AG researches, develops, manufactures, distributes, markets, and sells pharmaceutical medicines in Switzerland and internationally. The company offers Entresto, an angiotensin receptorneprilysin inhibitor to treat symptomatic chronic heart failure with reduced ejection fraction (HFrEF); Cosentyx to treat plaque psoriasis, pso riatic arthritis, ankylosing spondylitis, and nonradiographic axial spondy loarthritis; Kisqali, a selective oral cyclin dependent inhibitor of kinases 4 and 6 (CDK4/6); Promacta/Revolade to treat immune thrombocy... [Read more]
Financial Performance
In 2025, Novartis AG's revenue was $56.67 billion, an increase of 9.57% compared to the previous year's $51.72 billion. Earnings were $13.98 billion, an increase of 17.11%.
Financial numbers in USDNews
Novartis CEO warns of reality of Trump's drug pricing policy
Novartis' CEO warned Tuesday that the U.S. drug pricing policy under President Donald Trump poses a “very difficult situation” and the reality will soon catch up with both drugmakers and patients.
Novartis CEO warns of reality of Trump's drug pricing policy
Novartis' CEO warned Tuesday that the U.S. drug pricing policy under President Donald Trump poses a “very difficult situation” and the reality will soon catch up with both drugmakers and patients.
Novartis Stock Declines After Q1 Revenue Misses Expectations
Novartis Stock Declines After Q1 Revenue Misses Expectations
Market Update: Microsoft (MSFT), Novartis (NVS), Coca-Cola (KO) Performance Amidst Economic Concerns
Market Update: Microsoft (MSFT), Novartis (NVS), Coca-Cola (KO) Performance Amidst Economic Concerns
Novartis Dips As Generics Take A Bite Out Of Its First-Quarter Sales
Novartis stock fell early Tuesday on lighter-than-expected first-quarter earnings and sales amid U.S. generic erosion.
Novartis AG Earnings Call Transcript: Q1 2026
Q1 2026 saw robust growth from priority brands, offset by U.S. generic erosion and higher R&D spend. Guidance for low single-digit sales growth and core operating decline is reaffirmed, with H2 expected to show stronger momentum. Multiple pivotal pipeline readouts are anticipated in the second half.
Novartis (NVS) Reports Q1 Sales and Pipeline Progress
Novartis (NVS) Reports Q1 Sales and Pipeline Progress
Novartis (NVS) Reports Disappointing Q1 2026 Results Amid Generic Competition
Novartis (NVS) Reports Disappointing Q1 2026 Results Amid Generic Competition
Novartis CEO Warns of Drug Pricing Policy Impact on Pharma Sector
Novartis CEO Warns of Drug Pricing Policy Impact on Pharma Sector
The reality of MFN drug pricing is going to set in over 'next 18 months,' says Novartis CEO
President Donald Trump's drug pricing policy will have a "significant" impact on drugmakers and patients over the longer term, says Novartis CEO Vas Narasimhan.
Novartis Faces Challenges Ahead of Q1 2026 Earnings
Novartis Faces Challenges Ahead of Q1 2026 Earnings
Novartis Earnings Hit by Generic Competition
Novartis shares fall after weak Q1 hit by Entresto competition
Novartis reported first-quarter core operating profit and sales below market expectations, as generic competition for its top-selling heart drug Entresto weighed on results. Shares of the Swiss drugma...
Novartis misses in Q1 but sticks with full-year outlook
Novartis misses in Q1 but sticks with full-year outlook
Novartis CEO: We knew these first two quarters would be bumpy
Novartis CEO Vas Narasimhan discusses the company's first quarter earnings, which missed expectations amid increasing generic competition in the key U.S. market.
Novartis CEO warns reality of Trump's drug pricing policy will set in over 'the next 18 months'
Novartis' CEO warned Tuesday that U.S. drug pricing policy under President Donald Trump poses a "very difficult situation."
Novartis CEO: We knew these first two quarters would be bumpy
Novartis CEO Vas Narasimhan discusses the company's first quarter earnings, which missed expectations amid increasing generic competition in the key U.S. market.
Novartis (NVS) Reports Q1 Earnings Miss with Declining Sales
Novartis (NVS) Reports Q1 Earnings Miss with Declining Sales
European markets to open higher as Trump considers Iran peace proposal
European stocks are expected to open higher on Tuesday as investors assess the latest developments in the Iran war, and look ahead to earnings reports.
Novartis Q1 profit down on US generic erosion
Swiss drugmaker Novartis reported first-quarter core operating profit below market expectations on Tuesday, as generic competition for its top-selling heart drug Entresto weighed on sales.
Novartis delivered strong growth in priority brands and launches in Q1; FY 2026 guidance reaffirmed
Ad hoc announcement pursuant to Art. 53 LR First quarter Net sales declined -5% (cc 1 , -1% USD), as growth drivers were more than offset by US generic erosion Continued strong performance from priori...
Pharma bets a little-known cholesterol will underpin its next blockbuster heart drugs
Novartis, Amgen and Eli Lilly are among the pharmaceutical companies developing drugs to lower levels of a particularly bad form of cholesterol called Lp(a) and potentially prevent heart attacks. Lp(a...
Novartis AG (XSWX:NOVN) Q1 2026: Everything You Need To Know Ahead Of Earnings
Novartis AG (XSWX:NOVN) Q1 2026: Everything You Need To Know Ahead Of Earnings
Novartis (NVS) Secures Approval for Rhapsido in Treating Chronic Urticaria
Novartis (NVS) Secures Approval for Rhapsido in Treating Chronic Urticaria
Novartis Receives European Commission Approval For Rhapsido In Chronic Spontaneous Urticaria
(RTTNews) - Novartis (NVS) announced on Monday that the European Commission has approved Rhapsido (remibrutinib) for chronic spontaneous urticaria (CSU) in adult patients with an inadequate response t...